Products for Research Use Only

Tyroserleutide

CAT: 0013-GTR19157605-08Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0013-GTR19157605-08Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Tyroserleutide (YSL), isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.Tyroserleutide inhibits the growth and metastasis of human hepatocellular carcinoma (HCC) .Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells. Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression. Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells. Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration.Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice. (In Vitro) :Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells.Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression.Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells.Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration. (In Vivo) :Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice.
CAS Number
138168-48-6
Purity
>98% (HPLC)
Solubility
H2O
Smiles
CC (C) C[C@H] (NC ([C@@H] (NC ([C@@H] (N) CC1=CC=C (O) C=C1) =O) CO) =O) C (O) =O
Molecular Formula
C18H27N3O6
Molecular Weight
381.42
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.

Chemical Information

Tyroserleutide

Tyr-Ser-Leu is a tripeptide.

CAS Number138168-48-6
PubChem CID10045387
IUPAC Name(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoic acid
Molecular FormulaC18H27N3O6
Molecular Weight381.4
XLogP-3.1
Topological Polar Surface Area162
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count7
Rotatable Bond Count10
Heavy Atom Count27
Formal Charge0
Complexity505
SMILES
CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N
InChI
InChI=1S/C18H27N3O6/c1-10(2)7-14(18(26)27)20-17(25)15(9-22)21-16(24)13(19)8-11-3-5-12(23)6-4-11/h3-6,10,13-15,22-23H,7-9,19H2,1-2H3,(H,20,25)(H,21,24)(H,26,27)/t13-,14-,15-/m0/s1
InChIKey
MQGGXGKQSVEQHR-KKUMJFAQSA-N
Chemical Structure
2D Structure
2D structure of Tyroserleutide
CAS: 138168-48-6
CID: 10045387
Formula: C18H27N3O6
MW: 381.4
Interactive 3D Structure
Loading 3D structure...
Computed Properties
PropertyValue
Molecular Weight381.4
XLogP3-3.1
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count7
Rotatable Bond Count10
Exact Mass381.18998559
Monoisotopic Mass381.18998559
Topological Polar Surface Area162 Ų
Heavy Atom Count27
Formal Charge0
Complexity505
Isotope Atom Count0
Defined Atom Stereocenter Count3
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes